We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In add... Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Show more
Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de...
- Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – - EU Marketing Authorization Application (MAA) submission also validated...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a...
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved...
- Agreement includes access to any future licence extensions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an extended long-term reimbursement agreement with NHS England...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 7.325 | 1.499657075 | 488.445 | 498.77 | 478.78 | 1279648 | 489.51876701 | CS |
4 | 23.05 | 4.87603655441 | 472.72 | 498.77 | 466.01 | 1142553 | 480.22876191 | CS |
12 | 98.29 | 24.7282882158 | 397.48 | 498.77 | 391.7 | 1199018 | 457.32240814 | CS |
26 | 58.2 | 13.3007290262 | 437.57 | 498.77 | 391.01 | 1194718 | 436.0209709 | CS |
52 | 133.95 | 37.0211707479 | 361.82 | 498.77 | 340.2 | 1203535 | 403.78145569 | CS |
156 | 300.37 | 153.720573183 | 195.4 | 498.77 | 176.36 | 1430205 | 302.33063553 | CS |
260 | 322.43 | 186.010153456 | 173.34 | 498.77 | 165.23 | 1549958 | 267.82742735 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions